These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 23953823)

  • 1. Tumor regression and sirolimus-based therapy in lung transplantation.
    Hillen U; Griewank K; Sommerwerck U; Baba HA; Schadendorf D
    J Heart Lung Transplant; 2013 Sep; 32(9):938-9. PubMed ID: 23953823
    [No Abstract]   [Full Text] [Related]  

  • 2. Sirolimus and secondary skin-cancer prevention in kidney transplantation.
    Euvrard S; Morelon E; Rostaing L; Goffin E; Brocard A; Tromme I; Broeders N; del Marmol V; Chatelet V; Dompmartin A; Kessler M; Serra AL; Hofbauer GF; Pouteil-Noble C; Campistol JM; Kanitakis J; Roux AS; Decullier E; Dantal J;
    N Engl J Med; 2012 Jul; 367(4):329-39. PubMed ID: 22830463
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased risk of venous thromboembolism with a sirolimus-based immunosuppression regimen in lung transplantation.
    Ahya VN; McShane PJ; Baz MA; Valentine VG; Arcasoy SM; Love RB; Seethamraju H; Garrity E; Alex CG; Bag R; DeOliveira NC; Vigneswaran WT; Charbeneau J; Krishnan JA; Durazo-Arvizu R; Norwick L; Bhorade S
    J Heart Lung Transplant; 2011 Feb; 30(2):175-81. PubMed ID: 20947384
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sirolimus for the treatment of Kaposi sarcoma after renal transplantation: a series of 10 cases.
    Yaich S; Charfeddine K; Zaghdane S; El Aoud N; Jarraya F; Kharrat M; Hachicha J
    Transplant Proc; 2012 Nov; 44(9):2824-6. PubMed ID: 23146533
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of sirolimus with azathioprine in a tacrolimus-based immunosuppressive regimen in lung transplantation.
    Bhorade S; Ahya VN; Baz MA; Valentine VG; Arcasoy SM; Love RB; Seethamraju H; Alex CG; Bag R; Deoliveira NC; Husain A; Vigneswaran WT; Charbeneau J; Krishnan JA; Durazo-Arvizu R; Norwick L; Garrity E
    Am J Respir Crit Care Med; 2011 Feb; 183(3):379-87. PubMed ID: 20833822
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Conversion from a calcineurin inhibitor to a sirolimus-based therapy after renal transplantation - An update of existing recommendations].
    Arns W; Budde K; Eitner F; Gwinner W; Hugo C; Pressmar K; Weimann A; Witzke O
    Dtsch Med Wochenschr; 2011 Dec; 136(49):2554-9. PubMed ID: 22131077
    [No Abstract]   [Full Text] [Related]  

  • 7. Impact of early conversion from tacrolimus to sirolimus on chronic allograft changes in kidney recipients on rapid steroid withdrawal.
    Heilman RL; Cortese C; Geiger XJ; Younan K; Wadei HM; Mai ML; Reddy KS; Gonwa TA
    Transplantation; 2012 Jan; 93(1):47-53. PubMed ID: 22067270
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A retrospective study of conversion from tacrolimus-based to sirolimus-based immunosuppression in orthotopic liver transplant recipients.
    Yu S; He X; Yang L; Ma Y; Zhu X; Ju W; Huang J
    Exp Clin Transplant; 2008 Jun; 6(2):113-7. PubMed ID: 18816237
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunosuppressive treatment after solid organ transplantation and risk of post-transplant cutaneous squamous cell carcinoma.
    Ingvar A; Smedby KE; Lindelöf B; Fernberg P; Bellocco R; Tufveson G; Höglund P; Adami J
    Nephrol Dial Transplant; 2010 Aug; 25(8):2764-71. PubMed ID: 19729465
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: results from an open-label, randomized trial.
    Gaber AO; Kahan BD; Van Buren C; Schulman SL; Scarola J; Neylan JF;
    Transplantation; 2008 Nov; 86(9):1187-95. PubMed ID: 19005398
    [TBL] [Abstract][Full Text] [Related]  

  • 11. mTOR inhibitors: a myth, a cure for cancer or something in between?
    Wong G; Chapman JR; Craig JC
    Am J Transplant; 2012 May; 12(5):1075-6. PubMed ID: 22537261
    [No Abstract]   [Full Text] [Related]  

  • 12. [Dialysis and renal transplantation. Update 2012].
    Riegel W; Krüger B; Schnülle P
    Dtsch Med Wochenschr; 2012 Dec; 137(49):2567-70. PubMed ID: 23188637
    [No Abstract]   [Full Text] [Related]  

  • 13. Transplantation: Sirolimus for secondary SCC prevention in renal transplantation.
    Halleck F; Budde K
    Nat Rev Nephrol; 2012 Dec; 8(12):687-9. PubMed ID: 23026948
    [No Abstract]   [Full Text] [Related]  

  • 14. Prophylaxis with sirolimus and tacrolimus ± antithymocyte globulin reduces the risk of acute graft-versus-host disease without an overall survival benefit following allogeneic stem cell transplantation.
    Rosenbeck LL; Kiel PJ; Kalsekar I; Vargo C; Baute J; Sullivan CK; Wood L; Abdelqader S; Schwartz J; Srivastava S; Abonour R; Robertson MJ; Nelson RP; Cornetta K; Fausel CA; Farag SS
    Biol Blood Marrow Transplant; 2011 Jun; 17(6):916-22. PubMed ID: 20932925
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunosuppressive Medications and Squamous Cell Skin Carcinoma: Nested Case-Control Study Within the Skin Cancer after Organ Transplant (SCOT) Cohort.
    Coghill AE; Johnson LG; Berg D; Resler AJ; Leca N; Madeleine MM
    Am J Transplant; 2016 Feb; 16(2):565-73. PubMed ID: 26824445
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of sirolimus and tacrolimus on mortality and graft loss in liver transplant recipients with or without hepatitis C virus: an analysis of the Scientific Registry of Transplant Recipients Database.
    Watt KD; Dierkhising R; Heimbach JK; Charlton MR
    Liver Transpl; 2012 Sep; 18(9):1029-36. PubMed ID: 22641474
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Calcineurin inhibitor-related cholestasis complicating lung transplantation.
    Oto T; Okazaki M; Takata K; Egi M; Yamane M; Toyooka S; Sano Y; Snell GI; Goto K; Miyoshi S
    Ann Thorac Surg; 2010 May; 89(5):1664-5. PubMed ID: 20417810
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus.
    Bumbea V; Kamar N; Ribes D; Esposito L; Modesto A; Guitard J; Nasou G; Durand D; Rostaing L
    Nephrol Dial Transplant; 2005 Nov; 20(11):2517-23. PubMed ID: 15985508
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of everolimus on skin cancers in calcineurin inhihitor-treated heart transplant recipients.
    Euvrard S; Boissonnat P; Roussoulières A; Kanitakis J; Decullier E; Claudy A; Sebbag L
    Transpl Int; 2010 Aug; 23(8):855-7. PubMed ID: 19951373
    [No Abstract]   [Full Text] [Related]  

  • 20. A comparison of sirolimus vs. calcineurin inhibitor-based immunosuppressive therapies in liver transplantation.
    Zaghla H; Selby RR; Chan LS; Kahn JA; Donovan JA; Jabbour N; Genyk Y; Mateo R; Gagandeep S; Sher LS; Ramicone E; Fong TL
    Aliment Pharmacol Ther; 2006 Feb; 23(4):513-20. PubMed ID: 16441472
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.